Vedolizumab 300 MG Injection [Entyvio]

DRUG2 trials

Sponsors

Washington University School of Medicine, Shilpa Grover, MD, MPH

Conditions

Crohn Disease of Small IntestineImmune Checkpoint Inhibitor-Related Colitis

Phase 2

Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial

RecruitingNCT06841705

Shilpa Grover, MD, MPHImmune Checkpoint Inhibitor-Related Colitis

Start: 2025-07-15End: 2026-12-31Target: 80Updated: 2025-11-04

Phase 4

Defining Predictors of RT Response to Vedolizumab in IBD

CompletedNCT03142321

Washington University School of MedicineCrohn Disease of Small Intestine

Start: 2018-06-08End: 2024-10-28Updated: 2025-09-17